Quality of life and survival outcome for patients with nasopharyngeal carcinoma treated by volumetric-modulated arc therapy versus intensity-modulated radiotherapy

Background To evaluate the longitudinal changes of quality of life (QoL) and survival in patients with nasopharyngeal carcinoma (NPC) treated by volumetric-modulated arc therapy (VMAT) versus intensity-modulated radiotherapy (IMRT). Methods One hundred and forty non-distant metastatic NPC patients t...

Full description

Saved in:
Bibliographic Details
Published inRadiation oncology (London, England) Vol. 15; no. 1; pp. 84 - 9
Main Authors Huang, Tai-Lin, Tsai, Ming-Hsien, Chuang, Hui-Ching, Chien, Chih-Yen, Lin, Yu-Tsai, Tsai, Wen-Ling, Fang, Fu-Min
Format Journal Article
LanguageEnglish
Published London BioMed Central 19.04.2020
BioMed Central Ltd
BMC
Subjects
Adolescent
Adult
Aged
Biomedical and Life Sciences
Biomedicine
Cancer Research
Care and treatment
Clinical Radiation Oncology
Development and progression
EORTC
Female
Follow-Up Studies
Health aspects
Humans
Imaging
Intensity-modulated radiotherapy
Male
Methods
Middle Aged
Nasopharyngeal cancer
Nasopharyngeal carcinoma
Nasopharyngeal Carcinoma - mortality
Nasopharyngeal Carcinoma - radiotherapy
Nasopharyngeal Carcinoma - secondary
Nasopharyngeal Neoplasms - pathology
Nasopharyngeal Neoplasms - radiotherapy
Oncology
Organs at Risk - radiation effects
Patient outcomes
Quality of Life
Radiology
Radiotherapy
Radiotherapy Dosage
Radiotherapy, Intensity-Modulated - methods
Re-Irradiation
Surveys and Questionnaires
Survival Analysis
Survival Rate
Volumetric-modulated arc therapy
Young Adult
Taiwan
Nasopharyngeal carcinoma
Volumetric-modulated arc therapy
Intensity-modulated radiotherapy
EORTC
Quality of life
Online AccessGet full text
ISSN1748-717X
1748-717X
DOI10.1186/s13014-020-01532-4

Cover

Abstract Background To evaluate the longitudinal changes of quality of life (QoL) and survival in patients with nasopharyngeal carcinoma (NPC) treated by volumetric-modulated arc therapy (VMAT) versus intensity-modulated radiotherapy (IMRT). Methods One hundred and forty non-distant metastatic NPC patients treated by VMAT ( n  = 66) or IMRT ( n  = 74) with simultaneously integrated boost between March 2013 and December 2015 at a single institute were analyzed. QoL was prospectively assessed by the EORTC QLQ-C30 and HN35 questionnaires at the four time points: before RT, RT 42.4 Gy (20 fractions), and 3, 12 months after RT. Results The 3-year locoregional relapse-free survival, distant metastasis-free survival, failure-free survival, and overall survival rates were 96.6, 89.4, 86.1%, and 87.4 for the VMAT group, respectively, compared with 91.4, 90.0, 79.8, and 91.3% for the IMRT group ( p value > 0.05). The pattern of QoL changes was similar between the VMAT and IMRT group. No statistically or clinically significant difference in all the QoL scales was observed between VMAT and IMRT group at each time point. Compared to before RT, we observed statistically ( p <0.05) and clinically (difference of mean scores≧10) better outcome in global QoL and social functioning, but worse head and neck symptomatic outcome in swallowing, taste/smell, opening mouth, dry mouth, and sticky saliva at the time point of 1 year after RT for both groups. Conclusion The study provides the evidence that the tumor control, survival and changes of QoL is compatible for NPC patients treated by VMAT versus IMRT.
AbstractList Background To evaluate the longitudinal changes of quality of life (QoL) and survival in patients with nasopharyngeal carcinoma (NPC) treated by volumetric-modulated arc therapy (VMAT) versus intensity-modulated radiotherapy (IMRT). Methods One hundred and forty non-distant metastatic NPC patients treated by VMAT (n = 66) or IMRT (n = 74) with simultaneously integrated boost between March 2013 and December 2015 at a single institute were analyzed. QoL was prospectively assessed by the EORTC QLQ-C30 and HN35 questionnaires at the four time points: before RT, RT 42.4 Gy (20 fractions), and 3, 12 months after RT. Results The 3-year locoregional relapse-free survival, distant metastasis-free survival, failure-free survival, and overall survival rates were 96.6, 89.4, 86.1%, and 87.4 for the VMAT group, respectively, compared with 91.4, 90.0, 79.8, and 91.3% for the IMRT group (p value > 0.05). The pattern of QoL changes was similar between the VMAT and IMRT group. No statistically or clinically significant difference in all the QoL scales was observed between VMAT and IMRT group at each time point. Compared to before RT, we observed statistically (p<0.05) and clinically (difference of mean scoresâ§10) better outcome in global QoL and social functioning, but worse head and neck symptomatic outcome in swallowing, taste/smell, opening mouth, dry mouth, and sticky saliva at the time point of 1 year after RT for both groups. Conclusion The study provides the evidence that the tumor control, survival and changes of QoL is compatible for NPC patients treated by VMAT versus IMRT. Keywords: Nasopharyngeal carcinoma, Quality of life, Volumetric-modulated arc therapy, Intensity-modulated radiotherapy, EORTC
To evaluate the longitudinal changes of quality of life (QoL) and survival in patients with nasopharyngeal carcinoma (NPC) treated by volumetric-modulated arc therapy (VMAT) versus intensity-modulated radiotherapy (IMRT).BACKGROUNDTo evaluate the longitudinal changes of quality of life (QoL) and survival in patients with nasopharyngeal carcinoma (NPC) treated by volumetric-modulated arc therapy (VMAT) versus intensity-modulated radiotherapy (IMRT).One hundred and forty non-distant metastatic NPC patients treated by VMAT (n = 66) or IMRT (n = 74) with simultaneously integrated boost between March 2013 and December 2015 at a single institute were analyzed. QoL was prospectively assessed by the EORTC QLQ-C30 and HN35 questionnaires at the four time points: before RT, RT 42.4 Gy (20 fractions), and 3, 12 months after RT.METHODSOne hundred and forty non-distant metastatic NPC patients treated by VMAT (n = 66) or IMRT (n = 74) with simultaneously integrated boost between March 2013 and December 2015 at a single institute were analyzed. QoL was prospectively assessed by the EORTC QLQ-C30 and HN35 questionnaires at the four time points: before RT, RT 42.4 Gy (20 fractions), and 3, 12 months after RT.The 3-year locoregional relapse-free survival, distant metastasis-free survival, failure-free survival, and overall survival rates were 96.6, 89.4, 86.1%, and 87.4 for the VMAT group, respectively, compared with 91.4, 90.0, 79.8, and 91.3% for the IMRT group (p value > 0.05). The pattern of QoL changes was similar between the VMAT and IMRT group. No statistically or clinically significant difference in all the QoL scales was observed between VMAT and IMRT group at each time point. Compared to before RT, we observed statistically (p<0.05) and clinically (difference of mean scores≧10) better outcome in global QoL and social functioning, but worse head and neck symptomatic outcome in swallowing, taste/smell, opening mouth, dry mouth, and sticky saliva at the time point of 1 year after RT for both groups.RESULTSThe 3-year locoregional relapse-free survival, distant metastasis-free survival, failure-free survival, and overall survival rates were 96.6, 89.4, 86.1%, and 87.4 for the VMAT group, respectively, compared with 91.4, 90.0, 79.8, and 91.3% for the IMRT group (p value > 0.05). The pattern of QoL changes was similar between the VMAT and IMRT group. No statistically or clinically significant difference in all the QoL scales was observed between VMAT and IMRT group at each time point. Compared to before RT, we observed statistically (p<0.05) and clinically (difference of mean scores≧10) better outcome in global QoL and social functioning, but worse head and neck symptomatic outcome in swallowing, taste/smell, opening mouth, dry mouth, and sticky saliva at the time point of 1 year after RT for both groups.The study provides the evidence that the tumor control, survival and changes of QoL is compatible for NPC patients treated by VMAT versus IMRT.CONCLUSIONThe study provides the evidence that the tumor control, survival and changes of QoL is compatible for NPC patients treated by VMAT versus IMRT.
Abstract Background To evaluate the longitudinal changes of quality of life (QoL) and survival in patients with nasopharyngeal carcinoma (NPC) treated by volumetric-modulated arc therapy (VMAT) versus intensity-modulated radiotherapy (IMRT). Methods One hundred and forty non-distant metastatic NPC patients treated by VMAT (n = 66) or IMRT (n = 74) with simultaneously integrated boost between March 2013 and December 2015 at a single institute were analyzed. QoL was prospectively assessed by the EORTC QLQ-C30 and HN35 questionnaires at the four time points: before RT, RT 42.4 Gy (20 fractions), and 3, 12 months after RT. Results The 3-year locoregional relapse-free survival, distant metastasis-free survival, failure-free survival, and overall survival rates were 96.6, 89.4, 86.1%, and 87.4 for the VMAT group, respectively, compared with 91.4, 90.0, 79.8, and 91.3% for the IMRT group (p value > 0.05). The pattern of QoL changes was similar between the VMAT and IMRT group. No statistically or clinically significant difference in all the QoL scales was observed between VMAT and IMRT group at each time point. Compared to before RT, we observed statistically (p<0.05) and clinically (difference of mean scores≧10) better outcome in global QoL and social functioning, but worse head and neck symptomatic outcome in swallowing, taste/smell, opening mouth, dry mouth, and sticky saliva at the time point of 1 year after RT for both groups. Conclusion The study provides the evidence that the tumor control, survival and changes of QoL is compatible for NPC patients treated by VMAT versus IMRT.
To evaluate the longitudinal changes of quality of life (QoL) and survival in patients with nasopharyngeal carcinoma (NPC) treated by volumetric-modulated arc therapy (VMAT) versus intensity-modulated radiotherapy (IMRT). One hundred and forty non-distant metastatic NPC patients treated by VMAT (n = 66) or IMRT (n = 74) with simultaneously integrated boost between March 2013 and December 2015 at a single institute were analyzed. QoL was prospectively assessed by the EORTC QLQ-C30 and HN35 questionnaires at the four time points: before RT, RT 42.4 Gy (20 fractions), and 3, 12 months after RT. The 3-year locoregional relapse-free survival, distant metastasis-free survival, failure-free survival, and overall survival rates were 96.6, 89.4, 86.1%, and 87.4 for the VMAT group, respectively, compared with 91.4, 90.0, 79.8, and 91.3% for the IMRT group (p value > 0.05). The pattern of QoL changes was similar between the VMAT and IMRT group. No statistically or clinically significant difference in all the QoL scales was observed between VMAT and IMRT group at each time point. Compared to before RT, we observed statistically (p<0.05) and clinically (difference of mean scoresâ§10) better outcome in global QoL and social functioning, but worse head and neck symptomatic outcome in swallowing, taste/smell, opening mouth, dry mouth, and sticky saliva at the time point of 1 year after RT for both groups. The study provides the evidence that the tumor control, survival and changes of QoL is compatible for NPC patients treated by VMAT versus IMRT.
To evaluate the longitudinal changes of quality of life (QoL) and survival in patients with nasopharyngeal carcinoma (NPC) treated by volumetric-modulated arc therapy (VMAT) versus intensity-modulated radiotherapy (IMRT). One hundred and forty non-distant metastatic NPC patients treated by VMAT (n = 66) or IMRT (n = 74) with simultaneously integrated boost between March 2013 and December 2015 at a single institute were analyzed. QoL was prospectively assessed by the EORTC QLQ-C30 and HN35 questionnaires at the four time points: before RT, RT 42.4 Gy (20 fractions), and 3, 12 months after RT. The 3-year locoregional relapse-free survival, distant metastasis-free survival, failure-free survival, and overall survival rates were 96.6, 89.4, 86.1%, and 87.4 for the VMAT group, respectively, compared with 91.4, 90.0, 79.8, and 91.3% for the IMRT group (p value > 0.05). The pattern of QoL changes was similar between the VMAT and IMRT group. No statistically or clinically significant difference in all the QoL scales was observed between VMAT and IMRT group at each time point. Compared to before RT, we observed statistically (p<0.05) and clinically (difference of mean scores≧10) better outcome in global QoL and social functioning, but worse head and neck symptomatic outcome in swallowing, taste/smell, opening mouth, dry mouth, and sticky saliva at the time point of 1 year after RT for both groups. The study provides the evidence that the tumor control, survival and changes of QoL is compatible for NPC patients treated by VMAT versus IMRT.
Background To evaluate the longitudinal changes of quality of life (QoL) and survival in patients with nasopharyngeal carcinoma (NPC) treated by volumetric-modulated arc therapy (VMAT) versus intensity-modulated radiotherapy (IMRT). Methods One hundred and forty non-distant metastatic NPC patients treated by VMAT ( n  = 66) or IMRT ( n  = 74) with simultaneously integrated boost between March 2013 and December 2015 at a single institute were analyzed. QoL was prospectively assessed by the EORTC QLQ-C30 and HN35 questionnaires at the four time points: before RT, RT 42.4 Gy (20 fractions), and 3, 12 months after RT. Results The 3-year locoregional relapse-free survival, distant metastasis-free survival, failure-free survival, and overall survival rates were 96.6, 89.4, 86.1%, and 87.4 for the VMAT group, respectively, compared with 91.4, 90.0, 79.8, and 91.3% for the IMRT group ( p value > 0.05). The pattern of QoL changes was similar between the VMAT and IMRT group. No statistically or clinically significant difference in all the QoL scales was observed between VMAT and IMRT group at each time point. Compared to before RT, we observed statistically ( p <0.05) and clinically (difference of mean scores≧10) better outcome in global QoL and social functioning, but worse head and neck symptomatic outcome in swallowing, taste/smell, opening mouth, dry mouth, and sticky saliva at the time point of 1 year after RT for both groups. Conclusion The study provides the evidence that the tumor control, survival and changes of QoL is compatible for NPC patients treated by VMAT versus IMRT.
ArticleNumber 84
Audience Academic
Author Chuang, Hui-Ching
Huang, Tai-Lin
Chien, Chih-Yen
Tsai, Wen-Ling
Lin, Yu-Tsai
Fang, Fu-Min
Tsai, Ming-Hsien
Author_xml – sequence: 1
  givenname: Tai-Lin
  surname: Huang
  fullname: Huang, Tai-Lin
  organization: Department of Hematology and Oncology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine
– sequence: 2
  givenname: Ming-Hsien
  surname: Tsai
  fullname: Tsai, Ming-Hsien
  organization: Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine
– sequence: 3
  givenname: Hui-Ching
  surname: Chuang
  fullname: Chuang, Hui-Ching
  organization: Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine
– sequence: 4
  givenname: Chih-Yen
  surname: Chien
  fullname: Chien, Chih-Yen
  organization: Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine
– sequence: 5
  givenname: Yu-Tsai
  surname: Lin
  fullname: Lin, Yu-Tsai
  organization: Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine
– sequence: 6
  givenname: Wen-Ling
  surname: Tsai
  fullname: Tsai, Wen-Ling
  organization: Department of Cosmetics and Fashion Styling, Center for Environmental Toxin and Emerging-Contaminant Research, Cheng Shiu University
– sequence: 7
  givenname: Fu-Min
  surname: Fang
  fullname: Fang, Fu-Min
  email: ard3779@gmail.com
  organization: Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32307024$$D View this record in MEDLINE/PubMed
BookMark eNp9kl2L1DAUhousuB_6B7yQgDfedE2atmlvhGXxY2FBBAXvwpnkZCZDm4xJOsv8Hv-omQ-XGZElFw2nz_v2nNP3sjhz3mFRvGb0mrGufR8Zp6wuaUVLyhpelfWz4oKJuisFEz_Pju7nxWWMS0rrhtP-RXHOK04FreqL4ve3CQabNsQbMliDBJwmcQpru4aB-CkpPyIxPpAVJIsuRfJg04I4iH61gLBxc8yggqCs8yOQFBASajLbkLUfphFTsKocvZ6GXT2DJC0wwCoDGOIUiXUJXcxNHGEBtPUH7mXx3MAQ8dXheVX8-PTx--2X8v7r57vbm_tSNaJPpVBNrQUiE71qRYuCg6ZohGihFjNV855RpCC05qxpeWX6rm_ahhqGeX19w6-Ku72v9rCUq2DHPJ_0YOWu4MNcQkhWDShVr1RnGtoZM6uN0DNou5YboKwCla2z14e912qajahV3lyA4cT09I2zCzn3aylY23XVtpl3B4Pgf00YkxxtVDgM4NBPUVa8r-om_0-e0bd7dA65NeuMz45qi8ubthK87hsmMnX9HyofjaNVOVnG5vqJ4M3xCI-9_w1PBqo9oIKPMaB5RBiV24TKfUJlTqjcJVRuRd0_ImVTjpbfrsEOT0v5Xhrzd3Luglz6KbgciadUfwCsuv71
CitedBy_id crossref_primary_10_1002_pro6_1219
crossref_primary_10_3390_cancers16061217
crossref_primary_10_1002_cam4_4899
crossref_primary_10_1016_j_jrras_2024_101246
crossref_primary_10_1016_j_ctro_2022_08_011
crossref_primary_10_3389_fonc_2024_1424034
crossref_primary_10_23736_S0394_9508_24_05769_3
crossref_primary_10_1002_lio2_417
crossref_primary_10_1016_j_jormas_2024_102042
crossref_primary_10_1259_bjr_20201289
crossref_primary_10_3389_fonc_2022_1010131
crossref_primary_10_32628_IJSRST5241115
crossref_primary_10_1007_s00520_024_08655_4
crossref_primary_10_1016_j_clon_2023_11_031
crossref_primary_10_1186_s13014_021_01970_8
crossref_primary_10_1007_s00520_024_08412_7
Cites_doi 10.1023/A:1022070220328
10.1200/JCO.1999.17.3.1008
10.1016/j.ijrobp.2006.06.013
10.1016/j.oraloncology.2013.02.013
10.1007/s00066-013-0344-z
10.1016/j.radonc.2014.02.003
10.1016/j.clon.2011.06.006
10.1016/j.ijrobp.2007.12.054
10.1259/bjr/23807619
10.1200/JCO.2008.19.9109
10.1007/s00066-015-0824-4
10.1016/j.ijrobp.2009.06.090
10.1200/JCO.2007.11.5501
10.1016/j.meddos.2013.05.004
10.1120/jacmp.v12i4.3587
10.1200/JCO.1998.16.1.139
10.1016/j.radonc.2011.11.017
10.7785/tcrt.2012.500262
10.1016/j.radonc.2010.05.022
10.1093/jnci/85.5.365
10.1016/j.ejca.2012.04.005
10.7785/tcrt.2012.500342
10.1016/j.radonc.2012.08.013
10.1016/j.oraloncology.2015.08.005
10.1016/j.ejmp.2015.08.004
ContentType Journal Article
Copyright The Author(s) 2020
COPYRIGHT 2020 BioMed Central Ltd.
Copyright_xml – notice: The Author(s) 2020
– notice: COPYRIGHT 2020 BioMed Central Ltd.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.1186/s13014-020-01532-4
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic


MEDLINE
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: Open Access Journals (DOAJ)
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1748-717X
EndPage 9
ExternalDocumentID oai_doaj_org_article_c9cc8f508ffb4f7dba6863fa012ac32f
PMC7168825
A627349517
32307024
10_1186_s13014_020_01532_4
Genre Journal Article
Comparative Study
GeographicLocations Taiwan
GeographicLocations_xml – name: Taiwan
GrantInformation_xml – fundername: Chang Gung Memorial Hospital
  grantid: CMRPG8F1201-3
  funderid: http://dx.doi.org/10.13039/100012553
– fundername: Chang Gung Memorial Hospital
  grantid: CMRPG8F1201-3
– fundername: ;
  grantid: CMRPG8F1201-3
GroupedDBID ---
0R~
123
29P
2WC
53G
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
ABDBF
ABUWG
ACGFS
ACUHS
ADBBV
ADRAZ
ADUKV
AENEX
AFKRA
AFPKN
AHBYD
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AOIJS
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CS3
DIK
E3Z
EBD
EBLON
EBS
ESX
F5P
FYUFA
GROUPED_DOAJ
HMCUK
HYE
I-F
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
TUS
UKHRP
WOQ
WOW
~8M
AAYXX
ALIPV
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
7X8
5PM
ID FETCH-LOGICAL-c579t-7c54d7ee179c676e73ad0ef776a47bc43910e0a7dd315632f9895650f1e015953
IEDL.DBID M48
ISSN 1748-717X
IngestDate Wed Aug 27 01:25:10 EDT 2025
Thu Aug 21 13:50:14 EDT 2025
Fri Sep 05 07:19:09 EDT 2025
Tue Jun 17 21:25:55 EDT 2025
Tue Jun 10 20:41:31 EDT 2025
Thu Apr 03 07:09:21 EDT 2025
Tue Jul 01 03:39:27 EDT 2025
Thu Apr 24 23:05:32 EDT 2025
Sat Sep 06 07:29:34 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Nasopharyngeal carcinoma
Volumetric-modulated arc therapy
Intensity-modulated radiotherapy
EORTC
Quality of life
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c579t-7c54d7ee179c676e73ad0ef776a47bc43910e0a7dd315632f9895650f1e015953
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
OpenAccessLink https://doi.org/10.1186/s13014-020-01532-4
PMID 32307024
PQID 2392455303
PQPubID 23479
PageCount 9
ParticipantIDs doaj_primary_oai_doaj_org_article_c9cc8f508ffb4f7dba6863fa012ac32f
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7168825
proquest_miscellaneous_2392455303
gale_infotracmisc_A627349517
gale_infotracacademiconefile_A627349517
pubmed_primary_32307024
crossref_primary_10_1186_s13014_020_01532_4
crossref_citationtrail_10_1186_s13014_020_01532_4
springer_journals_10_1186_s13014_020_01532_4
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-04-19
PublicationDateYYYYMMDD 2020-04-19
PublicationDate_xml – month: 04
  year: 2020
  text: 2020-04-19
  day: 19
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Radiation oncology (London, England)
PublicationTitleAbbrev Radiat Oncol
PublicationTitleAlternate Radiat Oncol
PublicationYear 2020
Publisher BioMed Central
BioMed Central Ltd
BMC
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
– name: BMC
References EK Uzel (1532_CR2) 2013; 189
G Peng (1532_CR4) 2012; 104
AM Chen (1532_CR22) 2012; 85
WK So (1532_CR24) 2012; 48
FM Fang (1532_CR5) 2010; 97
NK Aronson (1532_CR11) 1993; 85
D Osoba (1532_CR14) 1998; 16
FM Fang (1532_CR21) 2008; 72
T Liu (1532_CR3) 2012; 11
S Rathod (1532_CR23) 2013; 49
N Lee (1532_CR9) 2009; 27
JO Deasy (1532_CR17) 2010; 76
R Guo (1532_CR15) 2015; 10
WC Chie (1532_CR10) 2003; 12
P Metcalfe (1532_CR27) 2013; 12
B Zhang (1532_CR16) 2015; 51
AW Lee (1532_CR6) 2014; 110
TF Lee (1532_CR7) 2011; 12
MK Kam (1532_CR19) 2007; 25
S Tribius (1532_CR25) 2015; 191
EH Pow (1532_CR18) 2006; 66
TF Lee (1532_CR8) 2012; 24
K Bjordal (1532_CR12) 1999; 17
SH Lu (1532_CR1) 2012; 104
D Ciardo (1532_CR26) 2015; 31
X Jin (1532_CR20) 2013; 38
P Fayers (1532_CR13) 1999
References_xml – volume: 12
  start-page: 93
  year: 2003
  ident: 1532_CR10
  publication-title: Qual Life Res
  doi: 10.1023/A:1022070220328
– volume: 17
  start-page: 1008
  year: 1999
  ident: 1532_CR12
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.1999.17.3.1008
– volume: 66
  start-page: 981
  year: 2006
  ident: 1532_CR18
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2006.06.013
– volume-title: EORTC QLQ-C30 scoring manual
  year: 1999
  ident: 1532_CR13
– volume: 49
  start-page: 634
  year: 2013
  ident: 1532_CR23
  publication-title: Oral Oncol
  doi: 10.1016/j.oraloncology.2013.02.013
– volume: 189
  start-page: 552
  year: 2013
  ident: 1532_CR2
  publication-title: Strahlenther Onkol
  doi: 10.1007/s00066-013-0344-z
– volume: 110
  start-page: 377
  year: 2014
  ident: 1532_CR6
  publication-title: Radiother Oncol
  doi: 10.1016/j.radonc.2014.02.003
– volume: 24
  start-page: 196
  year: 2012
  ident: 1532_CR8
  publication-title: Clin Oncol (R Coll Radiol)
  doi: 10.1016/j.clon.2011.06.006
– volume: 72
  start-page: 356
  year: 2008
  ident: 1532_CR21
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2007.12.054
– volume: 85
  start-page: e537
  year: 2012
  ident: 1532_CR22
  publication-title: Br J Radiol
  doi: 10.1259/bjr/23807619
– volume: 27
  start-page: 3684
  year: 2009
  ident: 1532_CR9
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.19.9109
– volume: 10
  start-page: 1
  issue: 7
  year: 2015
  ident: 1532_CR15
  publication-title: PLoS One
– volume: 191
  start-page: 501
  year: 2015
  ident: 1532_CR25
  publication-title: Strahlenther Onkol
  doi: 10.1007/s00066-015-0824-4
– volume: 76
  start-page: S58
  year: 2010
  ident: 1532_CR17
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2009.06.090
– volume: 25
  start-page: 4873
  year: 2007
  ident: 1532_CR19
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2007.11.5501
– volume: 38
  start-page: 418
  issue: 4
  year: 2013
  ident: 1532_CR20
  publication-title: Med Dosim
  doi: 10.1016/j.meddos.2013.05.004
– volume: 12
  start-page: 158
  year: 2011
  ident: 1532_CR7
  publication-title: J Appl Clin Med Phys
  doi: 10.1120/jacmp.v12i4.3587
– volume: 16
  start-page: 139
  year: 1998
  ident: 1532_CR14
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.1998.16.1.139
– volume: 104
  start-page: 324
  year: 2012
  ident: 1532_CR1
  publication-title: Radiother Oncol
  doi: 10.1016/j.radonc.2011.11.017
– volume: 11
  start-page: 415
  year: 2012
  ident: 1532_CR3
  publication-title: Technol Cancer Res Treat
  doi: 10.7785/tcrt.2012.500262
– volume: 97
  start-page: 263
  year: 2010
  ident: 1532_CR5
  publication-title: Radiother Oncol
  doi: 10.1016/j.radonc.2010.05.022
– volume: 85
  start-page: 365
  year: 1993
  ident: 1532_CR11
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/85.5.365
– volume: 48
  start-page: 2391
  year: 2012
  ident: 1532_CR24
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2012.04.005
– volume: 12
  start-page: 429
  year: 2013
  ident: 1532_CR27
  publication-title: Technol Cancer Res Treat
  doi: 10.7785/tcrt.2012.500342
– volume: 104
  start-page: 286
  year: 2012
  ident: 1532_CR4
  publication-title: Radiother Oncol
  doi: 10.1016/j.radonc.2012.08.013
– volume: 51
  start-page: 1041
  year: 2015
  ident: 1532_CR16
  publication-title: Oral Oncol
  doi: 10.1016/j.oraloncology.2015.08.005
– volume: 31
  start-page: 1015
  year: 2015
  ident: 1532_CR26
  publication-title: Phys Med
  doi: 10.1016/j.ejmp.2015.08.004
SSID ssj0045309
Score 2.3379517
Snippet Background To evaluate the longitudinal changes of quality of life (QoL) and survival in patients with nasopharyngeal carcinoma (NPC) treated by...
To evaluate the longitudinal changes of quality of life (QoL) and survival in patients with nasopharyngeal carcinoma (NPC) treated by volumetric-modulated arc...
Background To evaluate the longitudinal changes of quality of life (QoL) and survival in patients with nasopharyngeal carcinoma (NPC) treated by...
Abstract Background To evaluate the longitudinal changes of quality of life (QoL) and survival in patients with nasopharyngeal carcinoma (NPC) treated by...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 84
SubjectTerms Adolescent
Adult
Aged
Biomedical and Life Sciences
Biomedicine
Cancer Research
Care and treatment
Clinical Radiation Oncology
Development and progression
EORTC
Female
Follow-Up Studies
Health aspects
Humans
Imaging
Intensity-modulated radiotherapy
Male
Methods
Middle Aged
Nasopharyngeal cancer
Nasopharyngeal carcinoma
Nasopharyngeal Carcinoma - mortality
Nasopharyngeal Carcinoma - radiotherapy
Nasopharyngeal Carcinoma - secondary
Nasopharyngeal Neoplasms - pathology
Nasopharyngeal Neoplasms - radiotherapy
Oncology
Organs at Risk - radiation effects
Patient outcomes
Quality of Life
Radiology
Radiotherapy
Radiotherapy Dosage
Radiotherapy, Intensity-Modulated - methods
Re-Irradiation
Surveys and Questionnaires
Survival Analysis
Survival Rate
Volumetric-modulated arc therapy
Young Adult
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Na9VAEF-kB_Eiav2I1rKC4EGXJtnNbnKsxVIK9WSht2WzH_igTeQlOeTv8R91Jps8XirUi9fshGxmZucjmfkNIR_BIzsICwLLTVUzIW0KdrA0DHswIbqXVRGwwfnqu7y4Fpc3xc3eqC-sCYvwwJFxJ7aytgwQRoRQi6BcbWQpeTBgWI2Fh6D1Tat0SaaiDRYFT6ulRaaUJ12GmQPDVAncH8-ZWLmhCa3_b5u855TuF0ze-2s6OaPzZ-TpHEXS07j75-SRb16Qx1fzf_JD8jtCY4y0DfR2Ezw1jaPdAGYBFIu2Qw965inEq3TGVe0ofpCljcGpBmY7wkOB0OKgoaa9M3SqR_eO1iON9gyB_dld63D6F1wHQhpbuYAAIsqho5tYHN-Pe2Rb4zZzy9f4klyff_txdsHmcQzMFqrqmbKFcMp7OMJWKukVNy71QSlphKottvCmPjXKOQ5JIYimKiH5KtKQeWB6VfBX5KBpG_-GUGPSwIPjxgcu8kzWTjhThDKzKN2cJyRbpKPtjFWOIzNu9ZSzlFJHiWqQqJ4kqkVCPu_u-RWROh6k_opC31EiyvZ0AXRPz7qn_6V7CfmEKqPRFsD2rJlbGuAlEVVLn0oED4IYViXkaEUJZ9iulj8sSqdxCQvfGt8Onc4hfhU42gl48joq4W7PHIv4IcZKiFqp5-ql1ivN5ucEIQ5ZMqRWRUK-LIqsZ9vVPcC0t_-Dae_Ik3w6iIJl1RE56LeDfw-BXV8fT2f4D2XWTg4
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Li9UwFA46grgR31ZHiSC40GLbvNrleHEYhHHlwOxCmgdemGnltl309_hHPadNL7ejDLhNTrlJzvsm5zuEvAeP7CAsCGlhqjrl0mZgB0uTYg0mRPeyEgELnM-_y7ML_u1SXEaYHKyFOby_z0v5ucsx5k8xyQHHxYqU3yX3BAyiNG_kZrG6XLCsWopi_vndyvFM-Px_W-EDN3TzieSNe9LJ_Zw-Ig9j3EhPZkY_Jnd884TcP48340_J7xkMY6RtoFfb4KlpHO0GMAQgSrQdepAsTyFCpRFJtaP4FyxtDPYxMLsRfhQILbYWatprQ6cX6N7ReqSzBUMo__S6ddjvC8aBkM7FW0AAMeTQ0e38HL4fD8h2xm1jkdf4jFycfv2xOUtjA4bUClX1qbKCO-U9KK2VSnrFjMt8UEoarmqLRbuZz4xyjkEaCByvSki3RBZyD4deCfacHDVt418SakwWWHDM-MB4kcvacWdEKHNrsEaFJSRfuKNtRCfHJhlXespSSqlnjmrgqJ44qnlCPu6_-TVjc9xK_QWZvqdEXO1pAMRNRzXVtrK2DBC0hlDzoFyNq2PBgBs3FjaYkA8oMhq1H5ZnTSxigE0ijpY-kQgXBFGrSsjxihK01q6m3y1Cp3EKn7o1vh06XUDEyrGZE5zJi1kI92tm-GwfoqqEqJV4rja1nmm2PyfQcMiLIZkSCfm0CLKO1qq75dBe_R_5a_KgmFSOp3l1TI763eDfQNDW128nbf0DtqQ8pQ
  priority: 102
  providerName: Springer Nature
Title Quality of life and survival outcome for patients with nasopharyngeal carcinoma treated by volumetric-modulated arc therapy versus intensity-modulated radiotherapy
URI https://link.springer.com/article/10.1186/s13014-020-01532-4
https://www.ncbi.nlm.nih.gov/pubmed/32307024
https://www.proquest.com/docview/2392455303
https://pubmed.ncbi.nlm.nih.gov/PMC7168825
https://doaj.org/article/c9cc8f508ffb4f7dba6863fa012ac32f
Volume 15
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bi9NAFB72AuKLeDe6lhEEH3Q0aSaZ5EGkW3ZZCruIWujbMJmLFrqJNi2Y3-Mf9ZxJUjbrsvhUmDlJ53LOnO9kzoWQ16CRDcACx8YqLxhPdQjnYKYYxmACuk_zxGGA8_lFejbns0Wy2CN9uaNuAesbTTusJzVfr97__tV8AoH_6AU-Sz_UEdoFDA0hUG7xmPF9cujvi9CVj-9uFXgSe5cPAOEZAzNm0QfR3PiOgaLy-fz_PbWvqK3rLpXX7lW9ujq9T-51OJNOWsZ4QPZs-ZDcOe9u0h-RP23yjIZWjq6WzlJVGlpv4eAA1qPVdgOcaCkgWtplXq0pfrKlpcK6B2rdwJ8CocZSRGV1qaj3WLeGFg1tTzxM_c8uK4P1waAdCGkb7AUEgDm3NV227vOb5grZWpllFxTWPCbz05Nv0zPWFWxgOhH5hgmdcCOsBSHXqUitiJUJrRMiVVwUGoN8QxsqYUwMZiNwSJ6BeZaELrKw6HkSPyEHZVXaZ4QqFbrYmVhZF_NxlBaGG5W4LNIKY1rigET97kjdZTPHohor6a2aLJXtjkrYUel3VPKAvN0987PN5XEr9TFu-o4S83D7hmr9XXZiLXWudeYA5DpXcCdMgaOLnQK1rzRMMCBvkGUk8i8MT6su6AEmiXm35CTF9EKAckVAjgaUIOV60P2qZzqJXegaV9pqW8sxIFyOxZ9gTZ62TLgbc4xu_oDCAiIG7DmY1LCnXP7wScbBjgbjKwnIu56RZS-ctyza8_-e7wtyd-yljbMoPyIHm_XWvgR8tylGZF8sxIgcTiazrzP4PT65-PwFWqfpdOS_mYy8WP8F1fVTEg
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagSMAF8SZQwEhIHCAiiR07OZYV1QLdnlqpN8vxQ6zUJmiTHPJ7-KPMJN7VpqBKXOOJYnvesecbQt6DR7YQFvg402UVc2ESsIOFjrEGE6J7UeYeC5xXp2J5zr9f5BcBJgdrYfbP79NCfG5TjPljTHLAcbEs5rfJHTy5RJz8hVhsrS7PWVJui2L--d7M8Yz4_H9b4T03dP2K5LVz0tH9HD8kD0LcSI8mRj8it1z9mNxdhZPxJ-T3BIYx0MbTy7V3VNeWtj0YAhAl2vQdSJajEKHSgKTaUvwFS2uNfQz0ZoCPAqHB1kJ1c6XpeAPdWVoNdLJgCOUfXzUW-33BcyCkU_EWEEAM2bd0PV2H74Y9so2261DkNTwl58dfzxbLODRgiE0uyy6WJudWOgdKa4QUTjJtE-elFJrLymDRbuISLa1lkAYCx8sC0q088amDTS9z9owc1E3tXhCqdeKZt0w7z3iWispyq3NfpEZjjQqLSLrljjIBnRybZFyqMUsphJo4qoCjauSo4hH5uHvn14TNcSP1F2T6jhJxtccHIG4qqKkypTGFh6DV-4p7aSucHfMa3Lg2sMCIfECRUaj9MD2jQxEDLBJxtNSRQLggiFplRA5nlKC1Zjb8bit0Cofwqlvtmr5VGUSsHJs5wZ48n4RwN2eG1_YhqoqInInnbFHzkXr9cwQNh7wYkqk8Ip-2gqyCtWpv2LSX_0f-ltxbnq1O1Mm30x-vyP1sVD8ep-UhOeg2vXsNAVxXvRk19w_Dlj-U
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Zb9QwELaglSpeULlDCxgJiQeImsR2nDwux6ostEKCSn2zHB9lpTapNsnD_h7-KDM5VpuCKvEaTxQfc8Yz3xDyBiyyBbfAh4nOi5CnJgI9mOkQazDBu09z4bHA-eQ0PT7ji3NxvlXF32W7j1eSfU0DojSVzdG19b2IZ-lRHWMkEGLoA-aMJSG_S3YzkecQfu3OZosfi1Ebc8GifCyW-eebE4PU4fb_rZ23zNPN1Mkb96edWZrvk_uDP0lnPQM8IHdc-ZDsnQw35o_I7x4kY00rTy-X3lFdWlq3oCCAxWjVNrB4R8FzpQPCak3x1ywtNfY30Ks1fBQIDbYcKqsrTbvMdGdpsaa9ZkOI__CqstgHDJ4DIe2LuoAAfMu2pss-Tb5Zb5GttF0OxV_rx-Rs_vnnx-NwaMwQGiHzJpRGcCudA2E2qUydZNpGzkuZai4Lg8W8kYu0tJZBeAickGcQhonIxw42PRfsCdkpq9I9I1TryDNvmXae8SROC8utFj6LjcbaFRaQeDwdZQbUcmyecam66CVLVX-iCk5UdSeqeEDebd657jE7bqX-gIe-oUS87e5BtbpQg_gqkxuTeXBmvS-4l7bA2TGvwbxrAwsMyFtkGYVaAaZn9FDcAItEfC01SxFGCLxZGZDDCSVIs5kMvx6ZTuEQpsCVrmprlYAny7HJE-zJ054JN3NmmM4P3lZA5IQ9J4uajpTLXx2YOMTLEGSJgLwfGVkNWqy-ZdOe_x_5K7L3_dNcffty-vWA3Es66eNhnB-SnWbVuhfg1zXFy0F0_wCyL0lS
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Quality+of+life+and+survival+outcome+for+patients+with+nasopharyngeal+carcinoma+treated+by+volumetric-modulated+arc+therapy+versus+intensity-modulated+radiotherapy&rft.jtitle=Radiation+oncology+%28London%2C+England%29&rft.au=Huang%2C+Tai-Lin&rft.au=Tsai%2C+Ming-Hsien&rft.au=Chuang%2C+Hui-Ching&rft.au=Chien%2C+Chih-Yen&rft.date=2020-04-19&rft.pub=BioMed+Central+Ltd&rft.issn=1748-717X&rft.eissn=1748-717X&rft.volume=15&rft.issue=1&rft_id=info:doi/10.1186%2Fs13014-020-01532-4&rft.externalDocID=A627349517
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1748-717X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1748-717X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1748-717X&client=summon